Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
T-cell receptor specific for prostatic acid phosphatase antigen (null)
- Target
- null
- Molecular classification
- Receptor, T-cell receptor, Immune receptor, Antigen receptor
01
Overview
A T-cell receptor specific for the prostatic acid phosphatase (PAP) antigen is a membrane-bound heterodimeric immune receptor composed of alpha and beta chains, expressed on T lymphocytes. Its variable regions enable the recognition of peptide antigens derived from PAP, presented on major histocompatibility complex (MHC) molecules. Upon recognition, the TCR-CD3 complex initiates intracellular signal transduction, leading to T-cell activation, proliferation, and targeted cytotoxicity against prostate cells expressing PAP. Such receptor specificities are central to adaptive immune response and serve as valuable therapeutic modalities in cancer immunotherapy, particularly for prostate cancer.
- Other names
- TCR specific for PAPT-cell receptor targeting PAPT-cell receptor recognizing prostatic acid phosphatasePAP-specific TCR
02
Mechanism of action
Antigen recognition and signal transduction: TCR binds peptide-MHC complex presenting PAP peptide Induction of immune cytotoxic response: Activated T cells kill prostate cancer cells expressing PAP
03
Biological functions
Immune responseAntigen recognitionSignal transductionCellular activation
04
Disease associations
Cancer (specifically prostate cancer; PAP is a prostate tumor antigen)Other (potential use in immunotherapy for prostate cancer and research in autoimmune disorders)
05
Safety considerations
Off-target toxicity (risk of autoimmunity if PAP is expressed in normal tissues)Cytokine release syndrome (as with any engineered TCR therapy)Graft-vs-host disease (in adoptive cell transfer settings)
06
Biomarkers
PAP expression (in tumor tissue)TCR clonotype (PCR/NGS-based detection of PAP-specific TCRs in patient blood or tissue)
Beyond the preview
Go deeper on T-cell receptor specific for prostatic acid phosphatase antigen (null).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on T-cell receptor specific for prostatic acid phosphatase antigen (null).